Taken together, these data and the analysis of the primary tumors suggest that many primary melanomas are heterogeneous with respect to the BRAFV600E mutation, and that some of the metastasizing tumor subclones do not require the presence of the BRAF mutation. This evidence concerns the gene BRAF and neoplasm.